Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Intensive BP Treatment & Subsequent CVD Risk

J Am Coll Cardiol; ePub 2018 Mar 7; Phillips, et al

Individuals with lower baseline cardiovascular disease (CVD) risk had more harm than benefit from intensive treatment of hypertension, while those with higher risk had more benefit. This according to a study that examined the effect of baseline 10-year CVD risk on primary outcome events and all-cause serious adverse events (SAEs) in the Systolic Pressure Intervention Trial (SPRINT). Stratifying by quartiles of baseline 10-year CVD risk, Cox proportional hazards models were used to examine the associations of treatment group with primary outcomes events and SAEs. Researchers found:

  • Within each quartile, there was a lower rate of primary outcome vents in the intensive treatment group, with no differences in all-cause SAEs.
  • The number needed to treat to prevent primary outcomes decreased from 91 to 30 from the first to fourth quartiles.
  • The number need to harm for all-cause SAEs increased from 62 to 250.
  • There was significantly increasing benefit-to-harm ratio for the first, second, third, and fourth quartile, respectively.

Citation:

Phillips R, Xu J, Peterson LE, et al. Impact of cardiovascular risk on the relative benefit and harm of intensive treatment of hypertension. [Published online ahead of print March 7, 2018]. J Am Coll Cardiol. doi:10.1016/j.jacc.2018.01.074.

This Week's Must Reads

Reactogenicity & Immunogenicity of Tdap in Pregnancy, Vaccine; ePub 2018 Sep 13; Fortner, et al

Barriers to Implementation of Vaccine Standards, Vaccine; ePub 2018 Sep 20; Srivastav, et al

Intra-Season Waning of Influenza Vaccine Efficacy, Open Forum Infect Dis; ePub 2018 Sep 10; Ray, et al

Pneumococcal Disease in Older Adults After PCV13, Clin Infect Dis; ePub 2018 Sep 20; Pelton, et al

Mumps Outbreaks in Vaccinated US Populations, Clin Infect Dis; ePub 2018 Sep 10; Clemmons, et al

Must Reads in Cardiology

Wearable Cardioverter-Defibrillator Use After MI, N Engl J Med; 2018 Sep 27; Olgin, et al

Subjective Wellbeing and Cardiometabolic Health, BMJ; ePub 2018 Sep 25; Wootton, et al

Does Aspirin Prevent CV Events in Older Adults?, N Engl J Med; ePub 2018 Sep 16; McNeil, et al

Intensification of BP Treatment Upon Discharge, BMJ; ePub 2018 Sep 12; Anderson, Wray, et al

Detection & Management of Resistant Hypertension, Hypertension; ePub 2018 Sep 13; Carey, et al